title: Alternate sunitinib schedules in patients with metastatic renal cell carcinoma.
abstract: Sunitinib malate is an oral multitargeted tyrosine kinase inhibitor exhibiting antiangiogenic activity. Sunitinib demonstrated improved outcomes in comparison to interferon-α in a large phase III study of treatment naïve patients with metastatic renal cell carcinoma. Maintaining patients on sunitinib treatment is essential for a sustained disease control as higher exposure to sunitinib has been associated with an improved overall response rate, progression-free survival and overall survival. Various studies have compared the outcomes of patients undergoing sunitinib therapy based on modifications from their standard dose and schedule. Several studies have shown that switching to an alternate schedule with more frequent dose interruptions without affecting dose density over a 6-week cycle is associated with improved outcomes and increased tolerability.
authors: Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston.
authors: S
authors: S
authors: Kalra
authors: Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, USA.
authors: B I
authors: BI
authors: Rini
authors: Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston ejonasch@mdanderson.org.
authors: E
authors: E
authors: Jonasch
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000556:secondary; D004334:Drug Administration Schedule; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology; D011379:Prognosis; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011758:Pyrroles / Q000627:therapeutic use*; D000077210:Sunitinib
chemical_list: D020533:Angiogenesis Inhibitors; D007211:Indoles; D047428:Protein Kinase Inhibitors; D011758:Pyrroles; D000077210:Sunitinib
keywords: alternate schedule; drug administration schedule; renal cell carcinoma; sunitinib
references: Cancer Chemother Pharmacol. 2010 Jul;66(2):357-71
references: 19967539
references: J Clin Oncol. 2006 Jan 1;24(1):25-35
references: 16314617
references: Lancet Oncol. 2013 Nov;14(12):1233-42
references: 24140184
references: J Clin Oncol. 2012 Apr 20;30(12):1371-7
references: 22430274
references: N Engl J Med. 2007 Jan 11;356(2):115-24
references: 17215529
references: Int J Urol. 2013 May;20(5):478-83
references: 23113655
references: Urol Oncol. 2014 May;32(4):480-7
references: 24321258
references: J Clin Oncol. 2009 Sep 1;27(25):4068-75
references: 19652072
references: Biol Ther. 2012 Oct 16;2:5
references: 24392298
references: J Natl Compr Canc Netw. 2009 Jun;7(6):618-30
references: 19555584
references: Eur J Cancer. 2014 Apr;50(6):1084-9
references: 24559686
references: J Clin Oncol. 2007 Mar 1;25(7):884-96
references: 17327610
references: Clin Cancer Res. 2012 Jul 15;18(14):3961-71
references: 22573349
references: Jpn J Clin Oncol. 2014 Mar;44(3):270-7
references: 24474815
references: Cancer. 2012 Mar 1;118(5):1252-9
references: 21898376
references: J Urol. 2014 Mar;191(3):611-8
references: 24018239
references: Ann Oncol. 2013 Aug;24(8):2098-103
references: 23579815
references: Expert Opin Pharmacother. 2007 Oct;8(14):2359-69
references: 17927489
references: J Med Econ. 2012;15(6):1139-48
references: 22808923
references: J Clin Oncol. 2009 Aug 1;27(22):3584-90
references: 19487381